Company: CERO
Filing Date: 2025-07-21
Form Type: S-1
Source: 0001213900-25-066152
Chunk: 147

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-21
Form: S-1
Chunk 147
---
 to     
 Keystone      |            |
|:-----------------------|------:|---:|:----|:--------------------|-----------:|:----|:--------------|-----:|:--|:----|:--------------|-----------:|
| $                      |  1.40 |    |     |                     | 12,493,498 |     |               | 85.5 | % |     | $             | 17,490,897 |
| $                      |  2.00 |    |     |                     |  8,745,449 |     |               | 80.4 | % |     | $             | 17,490,897 |
| $                      |  8.67 | -3 |     |                     |  2,017,404 |     |               | 48.7 | % |     | $             | 17,490,897 |
| $                      | 10.00 |    |     |                     |  1,749,090 |     |               | 45.1 | % |     | $             | 17,490,897 |
| $                      | 20.00 |    |     |                     |    874,545 |     |               | 29.1 | % |     | $             | 17,490,897 |

| (1) | The purchase prices assume a discount                                                                   
 to the market price of our shares, in accordance with the terms of the New Keystone Purchase Agreement. |

| (2) | The denominator is based on 2,126,003 shares of our common stock outstanding on a fully diluted basis as of June 30, 2025 (gives effect to the conversion of all outstanding Preferred Shares, the exercise of all outstanding Warrants and options, and the exercise of remaining shares available pursuant to our 2024 Stock Plan and 2024 ESPP Plan, as amended from time to time), adjusted to include the issuance of the number of Keystone Purchase Shares set forth in the adjacent column which we would have issued to Keystone based on the applicable assumed purchase price per share. |

| (3) | Represents the last reported sales price of the Common Stock on June 30, 2025, as reported by Nasdaq, less a 10% discount. |

79 USE OF PROCEEDS All of the shares of our Common Stock offered by Keystone will be solely for Keystone’s account. We will not receive any of the proceeds from these sales